In addition, they recommend permanently discontinuing the drug if hypertensive crisis or hypertensive encephalopathy develops, and in those with ‘medically significant hypertension' that cannot be adequately controlled with antihypertensive drugs.16 Further advice has been published to help oncologists who may not be familiar with managing hypertension in their clinical practice.19,58–64 Here, we focus on the management of bevacizumab-induced hypertension in cervical and ovarian cancer patients as this is the main area of prescribing for the VEGF inhibitor in the UK. This evidence concerns the gene VEGFA and hypertensive disorder.